PDCD1 and melanoma: Single or combination immune checkpoint inhibitors, such as anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and anti-programmed cell death 1 (PD-1), associated with stereotactic RT showed remarkable and durable responses in patients with BM from melanoma without severe side effects.